Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00918333 · ClinicalTrials.gov registry record · Phase 1
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
A Phase 1 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma, sponsored by Mayo Clinic.
- Completed
- Registry status
- Phase 1
- Development phase
- 124
- Enrollment target
- 3
- Study locations
NCT00918333 is a Phase 1 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma that has completed, run by Mayo Clinic. The registered enrollment target is 124 participants, above the 55-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target (125% higher). The trial reports 3 study locations across 3 states.
The verdict
NCT00918333, a Phase 1 study of Anaplastic Large Cell Lymphoma and Angioimmunoblastic T-cell Lymphoma, has completed, sponsored by Mayo Clinic.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 124 participants
- Enrollment target
- 3
- Study locations
Study Summary
This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma that has come back. Panobinostat and everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- DRUG panobinostat
- OTHER pharmacological study
- DRUG everolimus
Study Locations (3)
Arizona
- Mayo Clinic in Arizona - Scottsdale
Maryland
- Mark O Hatfield-Warren Grant Magnuson Clinical Center - Bethesda
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 124 participants |
| Start Date | 2009-06 |
| Est. Completion | 2019-07-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00918333
The ClinicalTrials.gov registry entry for NCT00918333 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 124 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 55-participant average among 25 other Anaplastic Large Cell Lymphoma trials with a reported enrollment target (125% higher). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Anaplastic Large Cell Lymphoma appearing as the primary indexed condition, and to 4 interventions - of which laboratory biomarker analysis is the first listed.
NCT00918333 reports 3 study locations spanning 3 distinct geographic areas - top geographies include Arizona, Maryland, Minnesota.
Frequently Asked Questions
What is clinical trial NCT00918333 about?
NCT00918333 is a clinical study titled "Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma". This phase I/II trial studies the side effects and best dose of panobinostat and everolimus when given together and to see how well they work in treating patients with multiple myeloma, non-Hodgkin lymphoma, or Hodgkin lymphoma that has come back. Panobinostat and everolimus may stop the growth of c...
What is the current status of trial NCT00918333?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 124 participants. The study started on 2009-06. Estimated completion is 2019-07-16.
What conditions does trial NCT00918333 study?
This clinical trial studies the following conditions: Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue.
What interventions are being tested in trial NCT00918333?
The interventions under investigation include: laboratory biomarker analysis (OTHER), panobinostat (DRUG), pharmacological study (OTHER), everolimus (DRUG).
Who is sponsoring clinical trial NCT00918333?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00918333 being conducted?
This trial has 3 study locations across Arizona, Maryland, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Anaplastic Large Cell Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma
RECRUITING · Phase 1
-
Azacitidine and Abatacept in Relapsed or Refractory T-Cell Lymphoma
RECRUITING · Phase 1
-
A Phase I Trial Anti-CC Chemokine Receptor 4 Chimeric Antigen Receptor T Cells (CCR4 CAR T Cells) for CCR4 Expressing T-cell Malignancies Including Peripheral T-cell Non-Hodgkin Lymphoma (PTCL) and Cutaneous T-cell Non-Hodgkin Lymphoma (CTCL)
RECRUITING · Phase 1
-
A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)
RECRUITING · Phase 1
-
Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas
ACTIVE NOT RECRUITING · Phase 1
-
Phase 1 Study of Autologous CD30.CAR-T in Relapsed or Refractory CD30 Positive Non-Hodgkin Lymphoma
ACTIVE NOT RECRUITING · Phase 1
Explore more on PlainTrial
Anaplastic Large Cell Lymphoma
All registered trials for this condition
Angioimmunoblastic T-cell Lymphoma
All registered trials for this condition
Arizona
All trials with a study site in Arizona
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.